The Center has consolidated research administration into one unit, to align more appropriately with the reorganized CCSG Program structure. It provides centralized corporate sen/ices, maintains single Center wide operating committees, and has centrally managed research facilities/services to promote efficiency and effectiveness. The research administrative team at Fox Chase Cancer Center (FCCC) primarily consists of the Vice President for Research Administration, an Assistant Vice President and a Shared Facility Administrator. These individuals are experienced in all aspects of research administration and participate in national research administrative groups, such as the Alliance of Dedicated Cancer Centers, the National Council of University Administrators and the Cancer Centers Administrators Forum. In addition to the time spent in research administration, the three key individuals have various Center-wide administrative responsibilities. Collectively, these three individuals provide the administrative support to all Cancer Center Programs and centralized scientific shared Facilities. They work closely with the Center President and Senior Vice Presidents on important Center initiatives (see Senior Leadership Description section) and they serve as administrative representatives on Center-wide committees. Each is supported by a staff that works in tandem to provide budgetary, grants management, space planning, and post-award support to investigators. A single administrator has responsibility for managing the CCSG. This individual oversees all financial transactions of CCSG Facilities, coordinates the annual progress report, manages the CCSG budget and assures compliance with CCSG regulations. Certain research grant functions have been centralized to achieve efficiency and effectiveness for all Center investigators. These centralized departments routinely interact with Research Administration. The centralized management provides for checks and balances in meeting NIH and other agency grant regulations. All pre-award activities (grant budgets, compliance with funding agency regulations and completion of most administrative application documents) are coordinated through our Office of Sponsored Research. All post-award activities (monitoring effort reports, reviewing grant charges, overseeing subcontracting activities, and filing final financial reports) are coordinated through our Grants Management Department. Policies are in place to allocate and manage institutional funds that support research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
7P30CA006927-50
Application #
8475332
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
50
Fiscal Year
2013
Total Cost
$130,415
Indirect Cost
Name
Research Institute of Fox Chase Cancer Center
Department
Type
DUNS #
064367329
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Fahl, Shawn P; Coffey, Francis; Kain, Lisa et al. (2018) Role of a selecting ligand in shaping the murine ??-TCR repertoire. Proc Natl Acad Sci U S A 115:1889-1894
Jones, Caitlin E; Hammer, Anisha M; Cho, YouJin et al. (2018) Stromal PTEN Regulates Extracellular Matrix Organization in the Mammary Gland. Neoplasia 21:132-145
Shaikh, Talha; Wang, Lora S; Egleston, Brian et al. (2018) Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 41:59-64
Campbell, Kerry S; Cohen, Adam D; Pazina, Tatiana (2018) Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma. Front Immunol 9:2551
Blackman, Elizabeth; Ashing, Kimlin; Gibbs, Denise et al. (2018) The Cancer Prevention Project of Philadelphia: preliminary findings examining diversity among the African diaspora. Ethn Health :1-17
Fatkhullina, Aliia R; Peshkova, Iuliia O; Dzutsev, Amiran et al. (2018) An Interleukin-23-Interleukin-22 Axis Regulates Intestinal Microbial Homeostasis to Protect from Diet-Induced Atherosclerosis. Immunity 49:943-957.e9
Gupta, Sapna; Kelow, Simon; Wang, Liqun et al. (2018) Mouse modeling and structural analysis of the p.G307S mutation in human cystathionine ?-synthase (CBS) reveal effects on CBS activity but not stability. J Biol Chem 293:13921-13931
Sementino, Eleonora; Menges, Craig W; Kadariya, Yuwaraj et al. (2018) Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. J Cell Physiol 233:8952-8961

Showing the most recent 10 out of 1280 publications